DiagnaMed Expands with Drug and Clinical Research AI Platform
DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF) is expanding its BRAIN AGE® Brain Health AI Platform to create a potential drug discovery and clinical research AI platform. The company is leveraging EEG data from previous and future research studies to accelerate clinical trial development and discover novel treatments for neurological, psychiatric, and infectious diseases.
BRAIN AGE® estimates brain age by analyzing brain-wave activity and can assess if a brain is aging atypically or if a person is in the early stage of cognitive decline. The platform has been clinically validated in a peer-reviewed paper published in Frontiers in Neuroergonomics, demonstrating its potential for large-scale screening and brain optimization.
The expanded platform aims to accelerate patient recruitment for clinical trials, enhance data analysis, and support drug development decisions. It can also help individuals seek personalized diagnostics and interventions to potentially decrease cognitive decline.
DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF) sta espandendo la sua BRAIN AGE® Piattaforma AI per la Salute Cerebrale per creare una potenziale piattaforma di scoperta di farmaci e ricerca clinica. L'azienda sta sfruttando i dati EEG da studi di ricerca passati e futuri per accelerare lo sviluppo di sperimentazioni cliniche e scoprire nuovi trattamenti per malattie neurologiche, psichiatriche e infettive.
BRAIN AGE® stima l'età cerebrale analizzando l'attività delle onde cerebrali e può valutare se un cervello sta invecchiando in modo atipico o se una persona si trova nelle prime fasi di declino cognitivo. La piattaforma è stata validata clinicamente in un articolo peer-reviewed pubblicato in Frontiers in Neuroergonomics, dimostrando il suo potenziale per screening su larga scala e ottimizzazione del cervello.
La piattaforma ampliata mira ad accelerare il reclutamento di pazienti per sperimentazioni cliniche, migliorare l'analisi dei dati e supportare le decisioni di sviluppo dei farmaci. Può anche aiutare gli individui a cercare diagnosi e interventi personalizzati per ridurre potenzialmente il declino cognitivo.
DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF) está expandiendo su BRAIN AGE® Plataforma de IA para la Salud Cerebral para crear una potencial plataforma de descubrimiento de medicamentos e investigación clínica. La compañía está aprovechando los datos de EEG de estudios de investigación pasados y futuros para acelerar el desarrollo de ensayos clínicos y descubrir nuevos tratamientos para enfermedades neurológicas, psiquiátricas e infecciosas.
BRAIN AGE® estima la edad cerebral analizando la actividad de las ondas cerebrales y puede evaluar si un cerebro está envejeciendo de manera atípica o si una persona se encuentra en las primeras etapas de declive cognitivo. La plataforma ha sido valida clínica en un artículo revisado por pares publicado en Frontiers in Neuroergonomics, demostrando su potencial para el cribado a gran escala y optimización cerebral.
La plataforma expandida tiene como objetivo acelerar el reclutamiento de pacientes para ensayos clínicos, mejorar el análisis de datos y apoyar las decisiones de desarrollo de medicamentos. También puede ayudar a las personas a buscar diagnósticos e intervenciones personalizadas para potencialmente disminuir el declive cognitivo.
DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF)는 BRAIN AGE® 뇌 건강 AI 플랫폼을 확장하여 잠재적인 약물 발견 및 임상 연구 AI 플랫폼을 만들고 있습니다. 이 회사는 이전 및 미래 연구에서 EEG 데이터를 활용하여 임상 시험 개발을 가속화하고 신경학적, 정신적, 전염병에 대한 새로운 치료법을 발견하고 있습니다.
BRAIN AGE®는 뇌 파형 활동을 분석하여 뇌의 나이를 추정하고 뇌가 비정상적으로 노화하고 있는지 또는 개인이 인지 쇠퇴의 초기 단계에 있는지를 평가할 수 있습니다. 이 플랫폼은 Frontiers in Neuroergonomics에 발표된 동료 검토 논문에서 임상 검증을 받았으며, 대규모 스크리닝 및 뇌 최적화에 대한 잠재력을 입증했습니다.
확장된 플랫폼은 임상 시험을 위한 환자 모집을 가속화하고 데이터 분석을 향상시키며 약물 개발 결정을 지원하는 것을 목표로 하고 있습니다. 또한 개인이 인지 쇠퇴를 잠재적으로 줄이기 위한 맞춤형 진단 및介入을 찾는 데 도움을 줄 수 있습니다.
DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF) étend sa BRAIN AGE® Plateforme IA de Santé Cérébrale pour créer une plateforme potentielle de découverte de médicaments et de recherche clinique. L'entreprise exploite les données EEG provenant d'études de recherche passées et futures pour accélérer le développement des essais cliniques et découvrir de nouveaux traitements pour les maladies neurologiques, psychiatriques et infectieuses.
BRAIN AGE® estime l'âge cérébral en analysant l'activité des ondes cérébrales et peut évaluer si un cerveau vieillit de manière atypique ou si une personne est à un stade précoce de déclin cognitif. La plateforme a été cliniquement validée dans un article évalué par des pairs publié dans Frontiers in Neuroergonomics, démontrant son potentiel pour le dépistage à grande échelle et l'optimisation cérébrale.
La plateforme élargie vise à accélérer le recrutement de patients pour les essais cliniques, à améliorer l'analyse des données et à soutenir les décisions de développement des médicaments. Elle peut également aider les individus à rechercher des diagnostics et des interventions personnalisées pour potentiellement réduire le déclin cognitif.
DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF) erweitert seine BRAIN AGE® Gehirngesundheits-AI-Plattform, um eine potenzielle Plattform für die Arzneimittelforschung und klinische Studien zu schaffen. Das Unternehmen nutzt EEG-Daten aus früheren und zukünftigen Forschungsstudien, um die Entwicklung klinischer Studien zu beschleunigen und neuartige Behandlungen für neurologische, psychiatrische und infektiöse Erkrankungen zu entdecken.
BRAIN AGE® schätzt das Gehirnalter anhand der Analyse der Gehirnwellenaktivität und kann beurteilen, ob ein Gehirn atypisch altert oder ob eine Person sich in einem frühen Stadium des kognitiven Rückgangs befindet. Die Plattform wurde in einem von Fachkollegen überprüften Artikel in den Frontiers in Neuroergonomics klinisch validiert, was ihr Potenzial für groß angelegte Screenings und Gehirnoptimierungen belegt.
Die erweiterte Plattform zielt darauf ab, die Rekrutierung von Patienten für klinische Studien zu beschleunigen, die Datenanalyse zu verbessern und die Entscheidungen zur Arzneimittelentwicklung zu unterstützen. Sie kann auch Einzelpersonen helfen, personalisierte Diagnostik und Interventionen zu suchen, um potenziell den kognitiven Rückgang zu verringern.
- Expansion of BRAIN AGE® platform into drug discovery and clinical research
- Potential to accelerate clinical trial development and patient recruitment
- Ability to assess brain health and early stages of cognitive decline
- Clinical validation through peer-reviewed publication
- Low-cost and easy-to-use EEG headset for data collection
- None.
Leveraging proprietary EEG data from previous and future research studies with BRAIN AGE® Brain Health AI
Accelerating clinical trial development and discovering potential novel treatments for neurological, psychiatric and infectious diseases
TORONTO, Aug. 21, 2024 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a healthcare technology company focused on brain health using AI, announces it is expanding the use of its novel BRAIN AGE® Brain Health AI Platform (“BRAIN AGE®”) through leveraging its electroencephalograph (“EEG”) data from research studies and future data collection, and applying it to build a potential drug discovery and clinical research AI platform. EEG provides a real-time readout of brain-wave activity in different brain regions and can measure a drug effect on the brain. BRAIN AGE® has the potential to accelerate patient recruitment for clinical trials, data analysis, drug development go/no-go decisions and new treatment options for neurological, psychiatric and infectious diseases.
BRAIN AGE® Brain Health AI estimates brain age by recording brain-wave activity from multiple brain regions and calculating the data with a proprietary machine-learning model. Certain drugs acting on the brain can generate a consistent EEG effect and produce models useful for developing novel drug analogs1 and potential drug repurposing ideas. In studying the effects of drugs on the brain via EEG, researchers can classify and identify drugs according to their mechanism of action on brain activity.2
Clinical Validation of BRAIN AGE® Brain Health AI Platform
BRAIN AGE® Brain Health AI can assess if a brain is aging more quickly or more slowly than is typical for healthy individuals. Brain age is estimated by collecting neural activity data of the brain with a low-cost and easy-to-use electroencephalogram headset and calculating the data with a proprietary machine-learning model. In addition, BRAIN AGE® Brain Health AI can assess if a person has a healthy brain or is in the early stage of cognitive decline. Brain health is scored by taking a clinically validated assessment for brain resilience, vulnerability and performance functions. Individuals can seek out personalized diagnostics and interventions, such as medication or lifestyle changes, that may help decrease cognitive decline development or progression.
In a first-of-a-kind peer-reviewed paper in Frontiers in Neuroergonomics, titled “Brain-age estimation with a low-cost EEG-headset: effectiveness and implications for large-scale screening and brain optimization”3, BRAIN AGE®, as announced in a press release by Drexel University, Prof. Kounios was quoted regarding the clinical potential of BRAIN AGE®: “It can be used as a relatively inexpensive way to screen large numbers of people for vulnerability to age-related. And because of its low cost, a person can be screened at regular intervals to check for changes over time,” Kounios said. “This can help to test the effectiveness of medications and other interventions. And healthy people could use this technique to test the effects of lifestyle changes as part of an overall strategy for optimizing brain performance.”4
About DiagnaMed
DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF) is a healthcare technology company focused on brain health using AI. DiagnaMed is commercializing BRAIN AGE® Brain Health AI Platform, a world-first consumer brain health and wellness AI solution that estimates brain age and provides a brain health score. Visit DiagnaMed.com.
For more information, please contact:
Fabio Chianelli
Chairman and CEO
DiagnaMed Holdings Corp.
Tel: 416-800-2684
Email: info@diagnamed.com
Website: www.diagnamed.com
Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.
Cautionary Statement
Certain statements in this news release are forward-looking statements, including with respect to future plans, and other matters. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Such information can generally be identified by the use of forwarding-looking wording such as “will”, “may”, “expect”, “could”, “can”, “estimate”, “anticipate”, “intend”, “believe”, “projected”, “aims”, and “continue” or the negative thereof or similar variations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including but not limited to, business, economic and capital market conditions, the ability to manage operating expenses, and dependence on key personnel. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which the Company will operate in the future, anticipated costs, and the ability to achieve goals. Factors that could cause the actual results to differ materially from those in forward-looking statements include, the continued availability of capital and financing, litigation, failure of counterparties to perform their contractual obligations, loss of key employees and consultants, and general economic, market or business conditions. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption “Risk Factors” in Company’s management’s discussion and analysis for the three and six months ended March 31, 2024 (“MD&A”), dated May 29, 2024, which is available on the Company's profile at www.sedarplus.ca. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The reader is cautioned not to place undue reliance on any forward-looking information. The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
This news release does not constitute an offer to sell or the solicitation of an offer to buy, and shall not constitute an offer, solicitation or sale in any state, province, territory or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state, province, territory or jurisdiction.
Footnotes:
- Bewernitz M, Derendorf H. Electroencephalogram-based pharmacodynamic measures: a review. Int J Clin Pharmacol Ther. 2012 Mar;50(3):162-84. doi: 10.5414/cp201484. PMID: 22373830; PMCID: PMC3637024.
- Kalitin, Konstantin Y., et al. "Deep learning analysis of intracranial EEG for recognizing drug effects and mechanisms of action." arXiv preprint arXiv:2009.12984 (2020).
- Kounios John, Fleck Jessica I., Zhang Fengqing, Oh Yongtaek. Brain-age estimation with a low-cost EEG-headset: effectiveness and implications for large-scale screening and brain optimization. Frontiers in Neuroergonomics. 2024; Volume 5. DOI=10.3389/fnrgo.2024.1340732.
- https://drexel.edu/news/archive/2024/April/New-AI-Technology-Estimates-Brain-Age-Using-Low-Cost-EEG-Device
FAQ
What is DiagnaMed's BRAIN AGE® Brain Health AI Platform?
How does DiagnaMed (DGNMF) plan to use BRAIN AGE® in drug discovery?
Has DiagnaMed's BRAIN AGE® platform been clinically validated?
What are the potential applications of DiagnaMed's BRAIN AGE® technology?
